- Home
- SBS vs ROIV Comparison
SBS vs ROIV Comparison
Compare SBS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBS | ROIV |
|---|---|---|
| Founded | 1954 | 2014 |
| Country | Brazil | United Kingdom |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3B | 20.7B |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SBS | ROIV |
|---|---|---|
| Price | $27.83 | $27.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $27.56 |
| AVG Volume (30 Days) | 1.4M | ★ 4.5M |
| Earning Date | 03-16-2026 | 02-06-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.96 | $594.84 |
| P/E Ratio | $15.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.53 | $8.73 |
| 52 Week High | $30.63 | $30.33 |
Technical Indicators
Market Signals| Indicator | SBS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 49.52 |
| Support Level | $27.12 | $26.94 |
| Resistance Level | $30.31 | $27.94 |
| Average True Range (ATR) | 0.89 | 0.96 |
| MACD | -0.11 | -0.38 |
| Stochastic Oscillator | 44.44 | 18.54 |
Price Performance
Historical ComparisonAbout SBS Companhia de saneamento Basico
Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in the Sao Paulo State and supplies treated water and sewage services on a wholesale basis. The company operates in a single segment, which is Sanitation services.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.